Phase 1 13 trials
Phase 1
NCT05687136 Jun 2024 → Aug 2026 overdue metastatic malignant neoplasm National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT05711615 Feb 2024 → Nov 2026 expected dedifferentiated liposarcoma , leiomyosarcoma , myxofibrosarcoma , synovial sarcoma +1 National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1
NCT05868174 May 2023 → Dec 2024 overdue renal cell carcinoma Telix Pharmaceuticals (Innovations) Pty Limited
Recruiting
No outcome recorded
Phase 1
NCT04533750 Dec 2021 → Dec 2025 overdue hypopharynx squamous cell carcinoma , laryngeal squamous cell carcinoma , oral cavity squamous cell carcinoma , oropharynx squamous cell carcinoma National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04750954 Jul 2021 → Dec 2026 expected neuroendocrine neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT04702698 Jan → Mar 2021 —
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Completed
No outcome recorded
Phase 1
NCT04555577 Sep 2020 → Dec 2027 expected gliosarcoma M.D. Anderson Cancer Center
Active not recruiting
No outcome recorded
Phase 1
NCT04092270 May 2020 → Feb 2026 overdue endometrial endometrioid adenocarcinoma , fallopian tube carcinosarcoma , fallopian tube clear cell adenocarcinoma , fallopian tube endometrioid adenocarcinoma +12 National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT03983824 May 2020 → Jun 2027 expected acute myeloid leukemia National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1
NCT03724890 Nov 2018 → Sep 2021 cancer EMD Serono Research & Development Institute, Inc.
Completed
No outcome recorded
Phase 1
NCT03116971 May 2017 → Mar 2018 small cell lung carcinoma EMD Serono Research & Development Institute, Inc.
Terminated
No outcome recorded
Phase 1
NCT02516813 Sep 2015 → Mar 2021 cancer EMD Serono Research & Development Institute, Inc.
Completed
No outcome recorded
Phase 1
NCT02316197 Dec 2014 → Jun 2017 B-cell chronic lymphocytic leukemia , cancer Merck KGaA, Darmstadt, Germany
Completed
No outcome recorded
Show 3 more trials Phase 1/2 5 trials
Phase 1/2
NCT04172532 Jan 2021 → Aug 2026 overdue pancreatic adenocarcinoma National Cancer Institute (NCI)
Recruiting
No outcome recorded
Phase 1/2
NCT04071236 Oct 2020 → Apr 2027 castration-resistant prostate carcinoma , metastatic carcinoma in the bone , metastatic malignant neoplasm in the lymph nodes National Cancer Institute (NCI)
Suspended
No outcome recorded
Phase 1/2
NCT04068194 Apr 2020 → Jul 2027 expected cholangiocarcinoma , gallbladder carcinoma , metastatic malignant neoplasm National Cancer Institute (NCI)
Active not recruiting
No outcome recorded
Phase 1/2
NCT03770689 Mar 2019 → Jun 2021 —
EMD Serono Research & Development Institute, Inc.
Completed
No outcome recorded
Phase 1/2
NCT02813135 Aug 2016 → Feb 2031 expected childhood malignant neoplasm Gustave Roussy, Cancer Campus, Grand Paris
Recruiting
No outcome recorded